Aska Pharmaceutical Co
Aska Pharmaceutical Co., Ltd., commonly referred to as Aska Pharma, is a prominent player in the pharmaceutical industry, headquartered in Japan (JP). Established in 1941, the company has made significant strides in developing innovative healthcare solutions, particularly in the fields of prescription pharmaceuticals and over-the-counter products.
With a strong operational presence in Asia and beyond, Aska Pharma focuses on therapeutic areas such as cardiovascular, oncology, and infectious diseases. Their core offerings include unique formulations and advanced drug delivery systems that set them apart in a competitive market.
Recognised for their commitment to quality and research, Aska Pharmaceutical has achieved notable milestones, including strategic partnerships and a robust pipeline of new drugs. Their dedication to improving patient outcomes solidifies their position as a trusted name in the global pharmaceutical landscape.
-18 vs industry average
Aska Pharmaceutical Co’s score of 20 is lower than 35% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Part of the Sustainability team at Aska Pharmaceutical Co?
- Control how your company's emission story is told
- Respond to customers efficiently
- See who's viewing your profile
Industry Intensity
Pharmaceutical Preparation Manufacturing has below-average carbon intensity
Industry performance
The Pharmaceutical Preparation Manufacturing industry has reduced its overall emissions by 19% since 0
Emissions trajectory 2020 – 2025
Reported emissions
Scope 3 accounts for ••• of total emissions.
Aska Pharmaceutical Co's reported carbon emissions
In 2022, Aska Pharmaceutical Co, headquartered in Japan, reported total carbon emissions of approximately 10,780,000 kg CO2e. This figure includes 6,687,000 kg CO2e from Scope 1 emissions and 4,093,000 kg CO2e from Scope 2 emissions. Notably, there is no reported data for Scope 3 emissions. Comparatively, emissions in 2021 were approximately 12,251,000 kg CO2e, with Scope 1 and Scope 2 emissions at 7,209,000 kg CO2e and 5,042,000 kg CO2e, respectively. This indicates a reduction in total emissions of about 1,471,000 kg CO2e from 2021 to 2022. Despite these reductions, Aska Pharmaceutical Co has not set specific science-based targets for emissions reduction, nor have they made any formal climate pledges. The company’s emissions data is sourced directly from Aska Pharmaceutical Holdings Co., Ltd., with no cascading from a parent organization. Overall, Aska Pharmaceutical Co is actively monitoring its carbon footprint, but further commitments and targets would enhance its climate strategy.
Unlock detailed emission data
Access structured emission data, company specific factors and auditable source documents
Aska Pharmaceutical Co’s Climate Goals (2030 & 2050)
No climate goals have been disclosed for Aska Pharmaceutical Co yet.
Scope 3 top emissions categories
No scope 3 category breakdown has been disclosed yet.
Climate initiatives
Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact Climate Champions initiative
RE 100
Climate Action 100
Emissions comparison with industry peers
View similar organisations
Aska Pharmaceutical Co
Usage policy
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Where does DitchCarbondata come from?
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn moreCurious to see your top suppliers emissions?
Book a demo for a pilot project